BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 32128992)

  • 1. TAS-115 inhibits PDGFRα/AXL/FLT-3 signaling and suppresses lung metastasis of osteosarcoma.
    Yasuda N; Takenaka S; Nakai S; Nakai T; Yamada S; Imura Y; Outani H; Hamada K; Yoshikawa H; Naka N
    FEBS Open Bio; 2020 May; 10(5):767-779. PubMed ID: 32128992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic potential of TAS-115 via c-MET and PDGFRα signal inhibition for synovial sarcoma.
    Yamada S; Imura Y; Nakai T; Nakai S; Yasuda N; Kaneko K; Outani H; Takenaka S; Hamada K; Myoui A; Araki N; Ueda T; Itoh K; Yoshikawa H; Naka N
    BMC Cancer; 2017 May; 17(1):334. PubMed ID: 28511645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The MET/Vascular Endothelial Growth Factor Receptor (VEGFR)-targeted Tyrosine Kinase Inhibitor Also Attenuates FMS-dependent Osteoclast Differentiation and Bone Destruction Induced by Prostate Cancer.
    Watanabe K; Hirata M; Tominari T; Matsumoto C; Fujita H; Yonekura K; Murphy G; Nagase H; Miyaura C; Inada M
    J Biol Chem; 2016 Sep; 291(40):20891-20899. PubMed ID: 27539855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High Potency VEGFRs/MET/FMS Triple Blockade by TAS-115 Concomitantly Suppresses Tumor Progression and Bone Destruction in Tumor-Induced Bone Disease Model with Lung Carcinoma Cells.
    Fujita H; Gomori A; Fujioka Y; Kataoka Y; Tanaka K; Hashimoto A; Suzuki T; Ito K; Haruma T; Yamamoto-Yokoi H; Harada N; Sakuragi M; Oda N; Matsuo K; Inada M; Yonekura K
    PLoS One; 2016; 11(10):e0164830. PubMed ID: 27736957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma.
    Wang G; Sun M; Jiang Y; Zhang T; Sun W; Wang H; Yin F; Wang Z; Sang W; Xu J; Mao M; Zuo D; Zhou Z; Wang C; Fu Z; Wang Z; Duan Z; Hua Y; Cai Z
    Int J Cancer; 2019 Aug; 145(4):979-993. PubMed ID: 30719715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Tyrosine Kinase Inhibitor TAS-115 Attenuates Bleomycin-induced Lung Fibrosis in Mice.
    Koyama K; Goto H; Morizumi S; Kagawa K; Nishimura H; Sato S; Kawano H; Toyoda Y; Ogawa H; Homma S; Nishioka Y
    Am J Respir Cell Mol Biol; 2019 Apr; 60(4):478-487. PubMed ID: 30540913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exosome-transmitted linc00852 associated with receptor tyrosine kinase AXL dysregulates the proliferation and invasion of osteosarcoma.
    Li Q; Wang X; Jiang N; Xie X; Liu N; Liu J; Shen J; Peng T
    Cancer Med; 2020 Sep; 9(17):6354-6366. PubMed ID: 32673448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The novel VEGF receptor/MET-targeted kinase inhibitor TAS-115 has marked in vivo antitumor properties and a favorable tolerability profile.
    Fujita H; Miyadera K; Kato M; Fujioka Y; Ochiiwa H; Huang J; Ito K; Aoyagi Y; Takenaka T; Suzuki T; Ito S; Hashimoto A; Suefuji T; Egami K; Kazuno H; Suda Y; Nishio K; Yonekura K
    Mol Cancer Ther; 2013 Dec; 12(12):2685-96. PubMed ID: 24140932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcriptional activation of the Axl and PDGFR-α by c-Met through a ras- and Src-independent mechanism in human bladder cancer.
    Yeh CY; Shin SM; Yeh HH; Wu TJ; Shin JW; Chang TY; Raghavaraju G; Lee CT; Chiang JH; Tseng VS; Lee YC; Shen CH; Chow NH; Liu HS
    BMC Cancer; 2011 Apr; 11():139. PubMed ID: 21496277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gas6/Axl mediates tumor cell apoptosis, migration and invasion and predicts the clinical outcome of osteosarcoma patients.
    Han J; Tian R; Yong B; Luo C; Tan P; Shen J; Peng T
    Biochem Biophys Res Commun; 2013 Jun; 435(3):493-500. PubMed ID: 23684620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversal of c-MET-mediated Resistance to Cytotoxic Anticancer Drugs by a Novel c-MET Inhibitor TAS-115.
    Kunii E; Ozasa H; Oguri T; Maeno K; Fukuda S; Uemura T; Takakuwa O; Ohkubo H; Takemura M; Niimi A
    Anticancer Res; 2015 Oct; 35(10):5241-7. PubMed ID: 26408683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. lncRNA DANCR promotes tumor progression and cancer stemness features in osteosarcoma by upregulating AXL via miR-33a-5p inhibition.
    Jiang N; Wang X; Xie X; Liao Y; Liu N; Liu J; Miao N; Shen J; Peng T
    Cancer Lett; 2017 Oct; 405():46-55. PubMed ID: 28642170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Receptor tyrosine kinases in osteosarcoma: not just the usual suspects.
    Rettew AN; Getty PJ; Greenfield EM
    Adv Exp Med Biol; 2014; 804():47-66. PubMed ID: 24924168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Knockdown of AXL receptor tyrosine kinase in osteosarcoma cells leads to decreased proliferation and increased apoptosis.
    Zhang Y; Tang YJ; Man Y; Pan F; Li ZH; Jia LS
    Int J Immunopathol Pharmacol; 2013; 26(1):179-88. PubMed ID: 23527720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation.
    Rho JK; Choi YJ; Kim SY; Kim TW; Choi EK; Yoon SJ; Park BM; Park E; Bae JH; Choi CM; Lee JC
    Cancer Res; 2014 Jan; 74(1):253-62. PubMed ID: 24165158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AXL and MET receptor tyrosine kinases are essential for lung cancer metastasis.
    Choi YJ; Kim JH; Rho JK; Kim JS; Choi CM; Kim WS; Son J; Lee JC
    Oncol Rep; 2017 Apr; 37(4):2201-2208. PubMed ID: 28260071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutation.
    Nakade J; Takeuchi S; Nakagawa T; Ishikawa D; Sano T; Nanjo S; Yamada T; Ebi H; Zhao L; Yasumoto K; Matsumoto K; Yonekura K; Yano S
    J Thorac Oncol; 2014 Jun; 9(6):775-83. PubMed ID: 24828661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
    Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
    Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MerTK inhibition is a novel therapeutic approach for glioblastoma multiforme.
    Knubel KH; Pernu BM; Sufit A; Nelson S; Pierce AM; Keating AK
    Oncotarget; 2014 Mar; 5(5):1338-51. PubMed ID: 24658326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma.
    Kubo T; Piperdi S; Rosenblum J; Antonescu CR; Chen W; Kim HS; Huvos AG; Sowers R; Meyers PA; Healey JH; Gorlick R
    Cancer; 2008 May; 112(10):2119-29. PubMed ID: 18338812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.